CRISPR Therapeutics AG
CRSP
$57.58
-$2.42-4.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.80% | -103.80% | -75.99% | -77.61% | -138.43% |
| Total Depreciation and Amortization | 1.14% | -3.40% | -2.75% | -2.33% | -2.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 202.87% | 159.54% | 173.65% | 2.23% | -28.42% |
| Change in Net Operating Assets | -54.00% | 206.60% | -137.91% | 103.14% | 180.72% |
| Cash from Operations | -141.65% | -60.20% | -166.73% | -92.24% | 45.17% |
| Capital Expenditure | 51.92% | 72.70% | 81.42% | 80.57% | 79.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.91% | 108.05% | 97.36% | -221.01% | -172.52% |
| Cash from Investing | 88.66% | 107.87% | 96.99% | -227.30% | -174.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.15% | -7.91% | -88.64% | -89.78% | 430.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28.33% | -7.78% | -88.62% | -89.91% | 429.78% |
| Foreign Exchange rate Adjustments | 552.38% | -94.49% | 2,625.00% | 3.33% | -128.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 154.00% | 120.11% | -838.26% | -230.16% | -151.58% |